{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T08:40:49Z","timestamp":1648888849088},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T00:00:00Z","timestamp":1326412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T00:00:00Z","timestamp":1326412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/leu.2011.380","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T17:04:04Z","timestamp":1326474244000},"page":"1321-1328","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common \u03b2-subunit c of cytokine receptors"],"prefix":"10.1038","volume":"26","author":[{"given":"T","family":"Klag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"H\u00e4rtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Erben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,13]]},"reference":[{"key":"BFleu2011380_CR1","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J . Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619\u20131630.","journal-title":"Blood"},{"key":"BFleu2011380_CR2","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","volume":"85","author":"GQ Daley","year":"1988","unstructured":"Daley GQ, Baltimore D . Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312\u20139316.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011380_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2032Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2011380_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018\u20131029.","journal-title":"Lancet Oncol"},{"key":"BFleu2011380_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","volume":"29","author":"J Cortes","year":"2011","unstructured":"Cortes J, Hochhaus A, Hughes T, Kantarjian H . Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011; 29: 524\u2013531.","journal-title":"J Clin Oncol"},{"key":"BFleu2011380_CR6","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009; 114: 5271\u20135278.","journal-title":"Blood"},{"key":"BFleu2011380_CR7","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R . BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103: 3167\u20133174.","journal-title":"Blood"},{"key":"BFleu2011380_CR8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 2007; 109: 2147\u20132155.","journal-title":"Blood"},{"key":"BFleu2011380_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Medic 1996; 2: 561\u2013566.","journal-title":"Nat Medic"},{"key":"BFleu2011380_CR10","doi-asserted-by":"crossref","unstructured":"H\u00e4rtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P et al. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. J Cancer Res Clin Oncol; e-pub ahead of print 17 November 2011; PMID:22089930.","DOI":"10.1007\/s00432-011-1086-x"},{"issue":"S1","key":"BFleu2011380_CR11","first-page":"382","volume":"93","author":"N H\u00e4rtel","year":"2009","unstructured":"H\u00e4rtel N, Klag T, Hochhaus A, La Ros\u00e9e P . Overexpression of the IL3\/IL5\/GM-CSFR\u03b2 as potential mechanism leading to survival factor activation in response to ABL-inhibitor treatment. Haematologica 2009; 93 (S1): 382(abstract).","journal-title":"Haematologica"},{"key":"BFleu2011380_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","volume":"10","author":"FE Nicolini","year":"2010","unstructured":"Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk 2010; 10: 394\u2013399.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu2011380_CR13","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2009.52","volume":"23","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S . Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446\u20131454.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/138161211795049778","volume":"17","author":"M Wetzler","year":"2011","unstructured":"Wetzler M, Segal D . Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011; 17: 59\u201364.","journal-title":"Curr Pharm Des"},{"key":"BFleu2011380_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(85)80053-2","volume":"41","author":"R Palacios","year":"1985","unstructured":"Palacios R, Steinmetz M . Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985; 41: 727\u2013734.","journal-title":"Cell"},{"key":"BFleu2011380_CR16","first-page":"7149","volume":"62","author":"P La Ros\u00e9e","year":"2002","unstructured":"La Ros\u00e9e P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ . Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149\u20137153.","journal-title":"Cancer Res"},{"key":"BFleu2011380_CR17","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1073\/pnas.80.10.2931","volume":"80","author":"JS Greenberger","year":"1983","unstructured":"Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ . Demonstration of permanent factor-dependent multipotential (erythroid\/neutrophil\/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci USA 1983; 80: 2931\u20132935.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011380_CR18","first-page":"3603","volume":"53","author":"M Beran","year":"1993","unstructured":"Beran M, Pisa P, O\u2032Brien S, Kurzrock R, Siciliano M, Cork A et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993; 53: 3603\u20133610.","journal-title":"Cancer Res"},{"key":"BFleu2011380_CR19","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S et al. Mutation in the ATP-binding Pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res 2002; 62: 5995\u20135998.","journal-title":"Cancer Res"},{"key":"BFleu2011380_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","volume":"45","author":"CB Lozzio","year":"1975","unstructured":"Lozzio CB, Lozzio BB . Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321\u2013334.","journal-title":"Blood"},{"key":"BFleu2011380_CR21","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","volume":"85","author":"R Bhatia","year":"1995","unstructured":"Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM . Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85: 3636\u20133645.","journal-title":"Blood"},{"key":"BFleu2011380_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood.V97.9.2846","volume":"97","author":"NJ Donato","year":"2001","unstructured":"Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M . Down-regulation of interleukin-3\/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001; 97: 2846\u20132853.","journal-title":"Blood"},{"key":"BFleu2011380_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","volume":"16","author":"JF Dorsey","year":"2002","unstructured":"Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002; 16: 1589\u20131595.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5: 723\u2013731.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011380_CR25","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu2011380_CR26","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","volume":"68","author":"H Konig","year":"2008","unstructured":"Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R . Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68: 9624\u20139633.","journal-title":"Cancer Res"},{"key":"BFleu2011380_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H Konig","year":"2008","unstructured":"Konig H, Holyoake TL, Bhatia R . Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329\u20132338.","journal-title":"Blood"},{"key":"BFleu2011380_CR28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748\u2013755.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR29","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","volume":"105","author":"S Chu","year":"2005","unstructured":"Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093\u20132098.","journal-title":"Blood"},{"key":"BFleu2011380_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926\u2013935.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","volume":"47","author":"P La Rosee","year":"2010","unstructured":"La Rosee P, Deininger MW . Resistance to imatinib: mutations and beyond. Semin Hematol 2010; 47: 335\u2013343.","journal-title":"Semin Hematol"},{"key":"BFleu2011380_CR32","doi-asserted-by":"publisher","first-page":"e5428","DOI":"10.1371\/journal.pone.0005428","volume":"4","author":"F Robert","year":"2009","unstructured":"Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J . Altering chemosensitivity by modulating translation elongation. PLoS ONE 2009; 4: e5428.","journal-title":"PLoS ONE"},{"key":"BFleu2011380_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/leu.2008.3","volume":"22","author":"J Liu","year":"2008","unstructured":"Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 2008; 22: 791\u2013799.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR34","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.55","volume":"25","author":"EK Allan","year":"2011","unstructured":"Allan EK, Holyoake TL, Craig AR, Jorgensen HG . Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells. Leukemia 2011; 25: 985\u2013994.","journal-title":"Leukemia"},{"key":"BFleu2011380_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011380","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:44:29Z","timestamp":1648737869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,13]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFleu2011380"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.380","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,13]]},"assertion":[{"value":"20 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AH received research support by Novartis Pharmaceuticals, N\u00fcrnberg, Germany and Chemgenex Pharmaceuticals (Menlo Park, CA, USA). PL receives speaker honorarium from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}